- News Releases
CHICAGO — Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial. Led by Mayo Clinic, researchers found that ibrutinib and chemotherapy (bendamustine and rituximab, known as BR) reduced the risk of death or cancer progression by almost 80 percent in patients with previously treated CLL or SLL, compared to use of BR alone. MEDIA CONTACTS: Joe Dangor (on-site at ASCO), Mayo Clinic Public Affairs, 651-261-9089 (cell), firstname.lastname@example.org. Paul Scotti, Mayo Clinic Public Affairs, 904-953-0199 (office), email@example.com. https://www.youtube.com/watch?v=WTNKotg-hqI
No posts available.